Skip to main content
SpringerLink
Log in

Most FAERS safety signals lead to FDA regulatory action

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Dhodapkar MM, et al. Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study BMJ : 12 Oct 2022. Available from: URL: https://doi.org/10.1136/bmj-2022-071752

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Most FAERS safety signals lead to FDA regulatory action. Reactions Weekly 1928, 10 (2022). https://doi.org/10.1007/s40278-022-25275-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-022-25275-9

Search

Navigation